-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 5.1%
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Up 5.1%
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating)'s share price shot up 5.1% during trading on Thursday . The company traded as high as $11.63 and last traded at $11.63. 59,817 shares changed hands during trading, a decline of 97% from the average session volume of 2,000,791 shares. The stock had previously closed at $11.07.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on the stock. Truist Financial cut their target price on shares of Iovance Biotherapeutics to $18.00 in a research note on Tuesday, August 23rd. The Goldman Sachs Group lowered their target price on shares of Iovance Biotherapeutics from $64.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, July 1st. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $31.00 to $30.00 in a research report on Friday, August 5th. Piper Sandler cut their target price on Iovance Biotherapeutics from $20.00 to $13.00 and set a "neutral" rating on the stock in a research report on Friday, May 27th. Finally, Robert W. Baird lowered their price target on Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.80.
Get Iovance Biotherapeutics alerts:Iovance Biotherapeutics Stock Up 6.3 %
The business's fifty day moving average price is $11.83 and its 200 day moving average price is $12.90.
Iovance Biotherapeutics (NASDAQ:IOVA – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business earned ($0.53) earnings per share. As a group, sell-side analysts anticipate that Iovance Biotherapeutics, Inc. will post -2.53 EPS for the current fiscal year.Institutional Trading of Iovance Biotherapeutics
Several hedge funds have recently made changes to their positions in IOVA. Herold Advisors Inc. acquired a new stake in Iovance Biotherapeutics in the first quarter valued at about $33,000. Spire Wealth Management purchased a new stake in shares of Iovance Biotherapeutics in the first quarter valued at approximately $47,000. Lazard Asset Management LLC grew its holdings in Iovance Biotherapeutics by 38.5% during the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 934 shares during the period. Retirement Group LLC raised its position in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Iovance Biotherapeutics in the first quarter valued at $83,000.
About Iovance Biotherapeutics
(Get Rating)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Read More
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Rating)'s share price shot up 5.1% during trading on Thursday . The company traded as high as $11.63 and last traded at $11.63. 59,817 shares changed hands during trading, a decline of 97% from the average session volume of 2,000,791 shares. The stock had previously closed at $11.07.
在週四的交易中,IOVANCE BioTreateutics,Inc.(納斯達克代碼:IOVA-GET Rating)的股價飆升了5.1%。該公司股價一度漲至11.63美元,最新報11.63美元。59,817股股票在交易中易手,較2,000,791股的平均交易量下跌了97%。該股此前收盤報11.07美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of analysts recently weighed in on the stock. Truist Financial cut their target price on shares of Iovance Biotherapeutics to $18.00 in a research note on Tuesday, August 23rd. The Goldman Sachs Group lowered their target price on shares of Iovance Biotherapeutics from $64.00 to $18.00 and set a "buy" rating for the company in a research note on Friday, July 1st. Chardan Capital lowered their price objective on Iovance Biotherapeutics from $31.00 to $30.00 in a research report on Friday, August 5th. Piper Sandler cut their target price on Iovance Biotherapeutics from $20.00 to $13.00 and set a "neutral" rating on the stock in a research report on Friday, May 27th. Finally, Robert W. Baird lowered their price target on Iovance Biotherapeutics from $34.00 to $25.00 and set an "outperform" rating for the company in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $23.80.
一些分析師最近加入了對該股的看法。Truist Financial在8月23日(星期二)的一份研究報告中將Iovance BioTreateutics的目標價下調至18.00美元。7月1日,高盛夫婦在一份研究報告中將Iovance BioTreateutics的目標價從64.00美元下調至18.00美元,併為該公司設定了買入評級。在8月5日星期五的一份研究報告中,Chardan Capital將Iovance BioTreateutics的目標價從31.00美元下調至30.00美元。派珀·桑德勒在5月27日週五的一份研究報告中將其對Iovance BioTreateutics的目標價從20.00美元下調至13.00美元,並將該股的評級定為“中性”。最後,羅伯特·W·貝爾德在8月5日星期五的一份報告中將Iovance BioTreateutics的目標價從34.00美元下調至25.00美元,併為該公司設定了“跑贏大盤”的評級。一名分析師對該股的評級為賣出,兩名分析師發佈了持有評級,八名分析師對該股給予了買入評級。根據MarketBeat.com的數據,該公司的平均評級為“中等買入”,平均目標價為23.80美元.
Iovance Biotherapeutics Stock Up 6.3 %
Iovance BioTreatetics股價上漲6.3%
The business's fifty day moving average price is $11.83 and its 200 day moving average price is $12.90.
該業務的50日移動均線價格為11.83美元,200日移動均線價格為12.90美元。
Institutional Trading of Iovance Biotherapeutics
Iovance生物療法的制度性交易
Several hedge funds have recently made changes to their positions in IOVA. Herold Advisors Inc. acquired a new stake in Iovance Biotherapeutics in the first quarter valued at about $33,000. Spire Wealth Management purchased a new stake in shares of Iovance Biotherapeutics in the first quarter valued at approximately $47,000. Lazard Asset Management LLC grew its holdings in Iovance Biotherapeutics by 38.5% during the first quarter. Lazard Asset Management LLC now owns 3,357 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 934 shares during the period. Retirement Group LLC raised its position in Iovance Biotherapeutics by 85.1% in the first quarter. Retirement Group LLC now owns 4,350 shares of the biotechnology company's stock worth $72,000 after acquiring an additional 2,000 shares in the last quarter. Finally, MetLife Investment Management LLC acquired a new stake in Iovance Biotherapeutics in the first quarter valued at $83,000.
幾家對衝基金最近改變了他們在Iova的頭寸。Herold Advisors Inc.在第一季度收購了Iovance BioTreateutics的新股份,價值約3.3萬美元。Spire Wealth Management在第一季度購買了Iovance BioTreateutics的新股份,價值約47,000美元。Lazard Asset Management LLC在第一季度增持了Iovance BioTreateutics 38.5%的股份。Lazard Asset Management LLC在此期間額外收購了934股,現在擁有3357股這家生物技術公司的股票,價值5.5萬美元。退休集團LLC在第一季度將其在Iovance BioTreateutics的頭寸提高了85.1%。在上個季度增持了2,000股後,退休集團現在持有這家生物技術公司4,350股股票,價值72,000美元。最後,大都會人壽投資管理有限責任公司在第一季度收購了Iovance BioTreateutics的新股份,價值8.3萬美元。
About Iovance Biotherapeutics
關於愛萬斯生物治療學
(Get Rating)
(獲取評級)
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma.
Iovance BioTreateutics,Inc.是一家臨牀階段的生物技術公司,專注於開發癌症免疫治療產品並將其商業化,以利用患者免疫系統的力量根除癌細胞。該公司正在進行6項第二階段臨牀研究,包括其主要候選產品lifileucel的C-144-01,用於治療轉移性黑色素瘤;C-145-04,其候選產品lifileucel,用於復發、轉移或持續性宮頸癌;以及C-145-03,其候選產品LN-145,用於治療復發和/或轉移性頭頸部鱗狀細胞癌。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Iovance Biotherapeutics (IOVA)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Murphy USA Outperforming Other Mid-caps, But Is It A Buy Now?
- 免費獲取StockNews.com關於Iovance生物療法(IOVA)的研究報告
- 為什麼醫療產品製造商Repligen可能成為潛在收購對象
- 在10%的水平上,Arbor Realty Trust的股息值得嗎?
- 投資者應關注RF Industries
- Netflix可能剛剛觸底的兩個原因
- 墨菲美國的表現好於其他中型股,但它現在值得嗎?
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《愛的生物療法日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Iovance BioTreateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧